BACKGROUND: Infratentorial ependymoma is a common central nervous system tumor of childhood and in patients >1 year of age is treated with maximally feasible surgical resection and radiotherapy. Because of this tumor typically arises within the 4th ventricle and can invade the brainstem, patients are at risk for significant neurological impairment. PURPOSE: To characterize the incidence, evolution, and persistence of neurologic impairment in children with infratentorial ependymoma following maximal safe surgery and conformal or intensity-modulated radiation therapy (CRT/IMRT). PATIENTS AND METHODS: After surgical resection, 96 children with non-metastatic infratentorial ependymoma were enrolled on a phase II study of image-guided radiation therapy and were prospectively followed with interval comprehensive neurological examinations. Late adverse neurological severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. RESULTS: The most common deficits detected at baseline examination were limb dysmetria, cranial nerve VI/VII palsy, limb paresis, dysphagia, and truncal ataxia/hypotonia. When present, gait dysfunction and dysphagia were often severe. Oculomotor dysfunction, facial paresis, dysphagia, and gait impairment improved over time. With the exception of hearing loss, in the survivor cohort, very few severe late effects (CTCAE Grade 3/4/5) were present at 60 months survival. CONCLUSION: In general, neurological deficits were maximal in the post-operative period and either remained stable or improved during radiation and the post-treatment evaluation period. With the exception of hearing, the majority of chronic residual neurological deficits in this at-risk population are mild and only minimally intrude upon daily life.
BACKGROUND:Infratentorial ependymoma is a common central nervous system tumor of childhood and in patients >1 year of age is treated with maximally feasible surgical resection and radiotherapy. Because of this tumor typically arises within the 4th ventricle and can invade the brainstem, patients are at risk for significant neurological impairment. PURPOSE: To characterize the incidence, evolution, and persistence of neurologic impairment in children with infratentorial ependymoma following maximal safe surgery and conformal or intensity-modulated radiation therapy (CRT/IMRT). PATIENTS AND METHODS: After surgical resection, 96 children with non-metastatic infratentorial ependymoma were enrolled on a phase II study of image-guided radiation therapy and were prospectively followed with interval comprehensive neurological examinations. Late adverse neurological severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. RESULTS: The most common deficits detected at baseline examination were limb dysmetria, cranial nerve VI/VII palsy, limb paresis, dysphagia, and truncal ataxia/hypotonia. When present, gait dysfunction and dysphagia were often severe. Oculomotor dysfunction, facial paresis, dysphagia, and gait impairment improved over time. With the exception of hearing loss, in the survivor cohort, very few severe late effects (CTCAE Grade 3/4/5) were present at 60 months survival. CONCLUSION: In general, neurological deficits were maximal in the post-operative period and either remained stable or improved during radiation and the post-treatment evaluation period. With the exception of hearing, the majority of chronic residual neurological deficits in this at-risk population are mild and only minimally intrude upon daily life.
Authors: Thomas E Merchant; Raymond K Mulhern; Matthew J Krasin; Larry E Kun; Tani Williams; Chenghong Li; Xiaoping Xiong; Raja B Khan; Robert H Lustig; Frederick A Boop; Robert A Sanford Journal: J Clin Oncol Date: 2004-08-01 Impact factor: 44.544
Authors: Chiaho Hua; Johnnie K Bass; Raja Khan; Larry E Kun; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2008-04-18 Impact factor: 7.038
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: A C Mertens; Y Yasui; J P Neglia; J D Potter; M E Nesbit; K Ruccione; W A Smithson; L L Robison Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 50.717
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Matthew Koshy; Shayna Rich; Thomas E Merchant; Usama Mahmood; William F Regine; Young Kwok Journal: J Neurooncol Date: 2011-06-03 Impact factor: 4.130
Authors: Christopher P Millward; Conor Mallucci; Tim Jaspan; Donald Macarthur; Richard Heyward; Tim Cox; Kung Chong; Richard G Grundy Journal: Childs Nerv Syst Date: 2016-09-01 Impact factor: 1.475
Authors: Thomas E Merchant; Anne E Bendel; Noah D Sabin; Peter C Burger; Dennis W Shaw; Eric Chang; Shengjie Wu; Tianni Zhou; David D Eisenstat; Nicholas K Foreman; Christine E Fuller; Edwina Templeton Anderson; Juliette Hukin; Ching C Lau; Ian F Pollack; Fred H Laningham; Robert H Lustig; Floyd D Armstrong; Michael H Handler; Chris Williams-Hughes; Sandra Kessel; Mehmet Kocak; David W Ellison; Vijay Ramaswamy Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Atmaram S Pai Panandiker; Thomas E Merchant; Chris Beltran; Shengjie Wu; Shelly Sharma; Frederick A Boop; Jesse J Jenkins; Kathleen J Helton; Karen D Wright; Alberto Broniscer; Larry E Kun; Amar Gajjar Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-19 Impact factor: 7.038
Authors: Victoria W Willard; Heather M Conklin; Frederick A Boop; Shengjie Wu; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2014-01-22 Impact factor: 7.038